Observational studyHIV medicine2025

Real-world effectiveness and safety of switching to dolutegravir/lamivudine among people living with HIV-1 aged over 50 years who are virologically suppressed.

C Piñeiro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.